BAYESIAN MODELLING ASSESSING THE EFFECTIVENESS OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES- THE BEST STUDY
Author(s)
Mennini FS1, Baio G2, Capone A3, Marcellusi A1, Favato G4, Costa S5, Garganese G6, Picardo M7, Drummond M8, Jonsson B9, Scambia G10, Zweifel P111University of Tor Vergata, Rome, Italy, 2University College London (UK), London, United Kingdom, 3University o
OBJECTIVES: The cost-effectiveness of different Human Papillomavirus (HPV) vaccination programmes was already confirmed throughout a large body of modelling studies. An excess of uncertainty associated with the main parameters of commonly utilized models can be observed. The aim of this study was to assess the cost-effectiveness of a quadrivalent-based multi-cohort HPV vaccination strategy using a statistical Bayesian approach. METHODS: A full Bayesian Markov model was used, where all unknown quantities were associated with suitable probability distributions reflecting the state of science currently available. These distributions were updated by the observation of any Italian available data, and uncertainty was propagated through the entire model with a Markov Chain Monte Carlo procedure. The model was calibrated using age-specific incidence of invasive cervical cancer data. RESULTS: Base case (2 cohorts of girls aged 12 and 15 years) and other multi-cohort vaccination strategies under evaluation (3 and 4 cohorts) were cost-effective with a discounted cost per QALY gained corresponding to €12,013 (95% range €2,364 - €22,481), €13,232 (95% range €4,432 - €22,939), and €15,890 (95% range €7,179 - €25,139) for vaccination programmes based on 2, 3 and 4 cohorts, respectively. The overall expected effect of vaccination seems to be linked with the number of cohorts targeted. With a multi-cohort vaccination the combined reduction of HPV-related events occurred progressively early (range 3 – 6.5 years) compared with the vaccination of a single cohort. The analysis of the expected value of information showed that the uncertainty was always kept at a low level among different multi-cohort strategies. The cost associated with the achievement of the expected value of information ranged between €9 and €13 per patient. CONCLUSIONS: The quadrivalent-based multi-cohort HPV vaccination programme can provide excellent value for money spent and the Bayesian expected value-of-information analysis provides the most appropriate and feasible representation of this program’s true value.
Conference/Value in Health Info
2011-05, ISPOR 2011, Baltimore, MD, USA
Value in Health, Vol. 14, No. 3 (May 2011)
Code
PCN62
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine), Oncology, Respiratory-Related Disorders